Condition: Amyloid Light-chain Amyloidosis · Sponsor: Rajshekhar Chakraborty, MD
The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis. The study treatment is divided into cycles (C) and each cycle is 28 days (D). Study treatment is expected to last 6 months.
This description comes directly from the study's public registry record.
Central Nurse Navigator, RN · (212) 342 5162 · cancerclinicaltrials@cumc.columbia.edu
Always discuss trial participation with your own doctor first.
| Boston Medical Center | Boston, Massachusetts, United States | Not Yet Recruiting |
| Columbia University Irving Medical Center | New York, New York, United States | Recruiting |
| Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07110844